Relapsed and refractory aggressive B-cell lymphoma
Conditions
Interventions
experimental group:Sequential therapy of CART cells with different B cell targets
Sponsors
Beijing Boren Hospital Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Relapsed or refractory aggressive B-cell lymphoma diagnosed with positive target markers (lymphoma cells express therapeutic target antigens, such as CD19, CD22, CD20) (standards refer to NCCN Guidelines, 5th edition in 2017); relapsed aggressive B-cell lymphoma refers to patients with aggressive B-cell lymphoma whose tumor burden increased again after reaching CR, refractory aggressive B-cell lymphoma refers to patients with aggressive B-cell lymphoma who have not achieved CR after 4 courses of standard chemotherapy; 2. The patient must have evidence of evaluable disease, including minimal residual disease; 3. Aged 18-75 years, including boundary values; 4. The expected survival period is more than 3 months; 5. ECOG score 0-2 points; 6. Women of childbearing age who have a negative blood pregnancy test before the start of the trial and who agree to take effective contraceptive measures during the trial until the last follow-up.
Exclusion criteria
Exclusion criteria: 1. Primary central nervous system aggressive B-cell lymphoma or aggressive B-cell lymphoma involving the central nervous system; 2. Those with a history of epilepsy or other central nervous system diseases; 3. Active hepatitis B or hepatitis C virus infection, HIV, cytomegalovirus, EB virus infection or other uncured active infection; 4. Lactating patients; 5. Those who have used any gene therapy products before; 6. Any situation that the investigator believes may increase the risk of the subject or interfere with the test results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy evaluation index; | — |
Countries
China
Contacts
Public ContactHu Kai
Beijing Boren Hospital
Outcome results
None listed